Expertise in
10
conditions

Dr. Jay Carlson

Obstetrics and Gynecology
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 
Expertise in
10
conditions
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 

Overview

Jay Carlson is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri.

Dr. Carlson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Ovarian Cancer, Lymphadenectomy, and Hysterectomy.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 227 clinical trials.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

SJC-Women's Oncology
2055 S Fremont Ave Ste 200, Springfield, MO 65804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

225 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 9 Less Clinical Trials

10 Total Publications

Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Journal: Gynecologic oncology
Published: March 17, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Albert Bonebrake
Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Albert Bonebrake
Obstetrics and Gynecology

Grove Professional Pharmacy Inc

1001 E Primrose St, 
Springfield, MO 
 (2.0 miles away)
417-875-3000
Languages Spoken:
English
See accepted insurances

Albert Bonebrake is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Bonebrake is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Ureteroscopy.

Expertise in
14
conditions
Dr. Marcia Hernandez
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Marcia Hernandez
Obstetrics and Gynecology

Office

2115 S Fremont Ave Ste 1100, 
Springfield, MO 
 (2.1 miles away)
417-820-3554
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marcia Hernandez is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. She has been practicing medicine for over 17 years. Dr. Hernandez is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, Vaginal Cancer, and Oophorectomy.

Expertise in
12
conditions
Dr. Ashley Valenzuela
Obstetrics and Gynecology
Expertise in
12
conditions
Dr. Ashley Valenzuela
Obstetrics and Gynecology

Coxhealth-Gynecologic Oncology

3850 S National Ave, 
Springfield, MO 
 (2.2 miles away)
417-875-3065
Languages Spoken:
English
See accepted insurances

Ashley Valenzuela is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Valenzuela is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Cervical Cancer, Oophorectomy, and Salpingo-Oophorectomy.

Frequently Asked Questions about Dr. Jay Carlson

How do I make an appointment with Dr. Jay Carlson?

You can book an appointment with Dr. Jay Carlson by calling their office at 417-820-3554. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jay Carlson a top-rated expert for Ovarian Carcinosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jay Carlson is classified as an Distinguished expert for Ovarian Carcinosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jay Carlson specialize in?

While Dr. Jay Carlson is a Obstetrics and Gynecology, they have specific expertise in Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Jay Carlson participate in research or clinical trials?

Yes. Dr. Jay Carlson has published 10 articles and abstracts on conditions like Ovarian Carcinosarcoma. You can view a list of Dr. Jay Carlson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlson's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile